Loading...
•
Dec 31, 2022
Tscan Therapeutics Q4 2022 Earnings Report
TScan Therapeutics reported its financial results for Q4 2022 and highlighted upcoming milestones.
Key Takeaways
TScan Therapeutics reported a revenue of $3.1 million and a net loss of $18.7 million for the fourth quarter of 2022. The company ended the year with $120.0 million in cash and cash equivalents, expected to fund operations into Q2 2024.
Phase 1 umbrella trial for TSC-100 and TSC-101 in hematologic malignancies is on track.
Primary IND (T-Plex) clearance supports the concomitant use of multiple TCRs for solid tumor trials.
Ended 2022 with $120.0 million in cash and cash equivalents, funding operations into Q2 2024.
Three IND applications filed with the FDA for solid tumor program in December 2022 have been cleared.
Tscan Therapeutics
Tscan Therapeutics
Tscan Therapeutics Revenue by Segment
Revenue by Segment
Collab & License Revenue
CapyFin.com Forward Guidance
TScan Therapeutics anticipates several milestones in its hematologic malignancies and solid tumor programs, including enrolling patients, reporting clinical data, and expanding the ImmunoBank.
Positive Outlook
- Expects to enroll patients in all three arms in the Phase 1 umbrella trial for TSC-100 and TSC-101 and start reporting preliminary safety and biomarker data mid-year 2023.
- Expects to reach the recommended Phase 2 dose for TSC-100 and TSC-101 and report interim clinical data for the program by the end of 2023.
- Anticipate further expansion of the ImmunoBank by filing INDs for four TCRs throughout 2023.
- Anticipate sharing preliminary safety and biomarker data for the most advanced TCRs by the end of 2023.
- The Company expects to report initial multiplex therapy data for its first combination of TCRs under T-Plex in the first half of 2024.